The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).
 
Bilal Siddiqui
Research Funding - Regeneron (Inst)
 
Benedito Carneiro
Consulting or Advisory Role - ADC Therapeutics; Eisai; Seagen
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Dragonfly Therapeutics (Inst); MiNK Therapeutics (Inst); Pfizer (Inst); Pyxis (Inst); Regeneron (Inst); Repare Therapeutics (Inst)
 
Mark Stein
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Exelixis; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Vaccitech; Xencor
Research Funding - Advaxis (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals; Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Regeneron (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Dendreon; Sanofi
Consulting or Advisory Role - AstraZeneca/MedImmune; Dendreon; Sanofi
 
William Kelly
Honoraria - Amgen; Janssen Oncology
Consulting or Advisory Role - Amgen; Bayer; Janssen Oncology
Research Funding - Amgen (Inst); Bayer (Inst); BioClin Therapeutics (Inst); Endocyte (Inst); Exelixis (Inst); Janssen Oncology (Inst); Novartis (Inst); Regeneron (Inst); Roche (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
David Wise
Stock and Other Ownership Interests - Doximity
Honoraria - OncLive
Consulting or Advisory Role - Accutar Biotech; Alphasights; AstraZeneca; Bayer; Gerson Lehrman Group; Guidepoint Global; K36; Leap Therapeutics; OncoC4; Pfizer; silverlight
Travel, Accommodations, Expenses - Bayer; Bayer; Pfizer
 
Kai Tsao
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb/Sanofi; Eisai; Exelixis; Guardant Health; Sanofi/Aventis
Research Funding - Exelixis
 
Gerald Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Clinical Care Options
Consulting or Advisory Role - Abbvie (Inst); BostonGene (Inst); BostonGene (Inst); BridgeBio Pharma (Inst); EMD Serono; Fujifilm (Inst); Inspirna (Inst); Jubilant Pharmaceuticals (Inst); Merck (Inst); Navire (Inst); Predicine (Inst); Regeneron (Inst); Sanofi (Inst); Silicon Therapeutics (Inst); Silicon Therapeutics (Inst); Teon Therapeutics (Inst); Turning Point Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ABL Bio (Inst); Accutar Biotech (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); American Society of Clinical Oncology (Inst); Amgen (Inst); ARMO BioSciences (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biomea Fusion (Inst); Biothera (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Celldex (Inst); Centessa Pharmaceuticals (Inst); Ciclomed (Inst); Conjupro Biotherapeutics (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); Eikon Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Freenome (Inst); Fujifilm (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Harbour BioMed (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunitas (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jazz Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Jubilant Pharmaceuticals (Inst); Kineta (Inst); Kolltan Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); MD Anderson Cancer Center (Inst); MedImmune (Inst); Merck (Inst); Metabomed (Inst); Millennium (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); National Institute of Health (NIH) (Inst); Navire (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); OncoMed (Inst); Oncorus (Inst); Oncothyreon (Inst); Phanes Therapeutics (Inst); Poseida (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Pyramid Biosciences (Inst); Pyxis (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Roche (Inst); Samumed (Inst); Sapience Therapeutics (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst); Silicon Therapeutics (Inst); Simcha Therapeutics (Inst); Sirnaomics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tallac Therapeutics (Inst); Tango Therapeutics (Inst); Tarus Therapeutics (Inst); Tarveda Therapeutics (Inst); TeneoBio (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst); Zhuhai Yufan Biotechnologies (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute; Synthorx/Sanofi
 
Przemyslaw Twardowski
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Astellas Pharma; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Seagen; Tolma
 
Xin Gao
Consulting or Advisory Role - ADC Therapeutics; Arvinas; Bayer; Flare Therapeutics; Hinova Pharmaceuticals; Loxo/Lilly
Research Funding - ALX Oncology (Inst); Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Bayer (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Regeneron (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)
 
Joseph Kim
Consulting or Advisory Role - Clovis Oncology; EMD Serono; Halda Therapeutics; Janssen Biotech; Janssen Oncology; Sanofi
Research Funding - ADC Therapeutics (Inst); Cosmo Pharmaceuticals; Dendreon (Inst); Exelixis (Inst); Hummingbird (Inst); IgM Biosciences (Inst); Janux Therapeutics (Inst); Regeneron (Inst); Roche (Inst)
 
Edward Gelmann
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); Johnson & Johnson (I); Lilly (I)
Research Funding - Regeneron (Inst)
Expert Testimony - Sanofi
 
Pradeep Thanigaimani
Employment - Regeneron
Stock and Other Ownership Interests - Celularity Inc; Inovio Pharmaceuticals; Lilly; Mannkind; Novo Nordisk; Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Fang Fang
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Frank Seebach
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Israel Lowy
Employment - Regeneron
Leadership - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Matthew Ingham
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Michael Kinnaman
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Consulting or Advisory Role - Cardinal Health
 
Sabina Sandigursky
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Elizabeth Miller
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron